Posted by Michael Wonder on 20 Oct 2016
Oral Otezla (apremilast) receives positive NICE recommendation for adults with chronic plaque psoriasis
20 October 2016 - Approved by NICE for patients with severe plaque psoriasis as defined by PASI and DLQI greater than or equal to 10.
Celgene announced today that adult patients in England and Wales with chronic plaque psoriasis will now have access to oral Otezla (apremilast) following a positive final appraisal determination from NICE.
The decision is the conclusion of a NICE rapid review and ensures patients in England and Wales will join those in Scotland, who have been benefitting from access to Otezla since it was recommended by the Scottish Medicines Consortium in June 2015.
